Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ilka Santoro

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER

Journal of Thoracic Oncology

Respiratory Medicine

English

Related publications

An Update on the Safety of Nivolumab for the Treatment of Advanced Melanoma

Expert Opinion on Drug Safety

English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population

Journal of Thoracic Oncology

Respiratory Medicine

English

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

PD-L1 Expression in Advanced NSCLC: Insights Into Risk Stratification and Treatment Selection From a Systematic Literature Review

Cancer Research

Respiratory Medicine

English

P1.01-14 Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Forensic Medicine

English

The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer

International Journal of Cancer

Cancer Research

English